NCT03841110 2023-05-01FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid TumorsFate TherapeuticsPhase 1 Completed37 enrolled
NCT03276468 2023-01-10Evaluation of Atezolizumab-Venetoclax-Obinutuzumab Combination in Relapse/Refractory LymphomasThe Lymphoma Academic Research OrganisationPhase 2 Completed136 enrolled
NCT02729896 2020-12-23A Study Evaluating Safety and Efficacy of Obinutuzumab, Polatuzumab Vedotin (Pola), and Atezolizumab (Atezo) in Participants With Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab, Atezo, and Pola in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)Hoffmann-La RochePhase 1/2 Completed36 enrolled 22 charts
NCT02220842 2020-01-27A Safety and Pharmacology Study of Atezolizumab (MPDL3280A) Administered With Obinutuzumab or Tazemetostat in Participants With Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell LymphomaHoffmann-La RochePhase 1 Completed96 enrolled